TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company's shares are also now DTC eligible, significantly enhancing the accessibility and efficiency of trading for U.S. investors. Tempra
Technology, Biotechnology, Pharmaceuticals, Health
2026-07-30 7:00 AM EDT | TempraMed Technologies Ltd.
Bachem Confirms Growth and Expects a Strong Second Half 2026
Bubendorf, Switzerland--(Newsfile Corp. - July 30, 2026) - Ad hoc announcement pursuant to Art. 53 LR Media Release Group sales grew to CHF 326.4 million (+4.3% compared to the prior-year period, +7.3% in local currencies). EBITDA amounted to CHF 82.8 million (-9.0% compared to the prior-year period, -4.2% in local currencies) with a margin of 25.4% (prior-year period: 29.1%).
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-07-30 12:56 AM EDT | Bachem Holding AG
Visionary Holdings' Subsidiary Nanjing Tuoyuanjian Health Technology Co., Ltd. Enters into Distribution Agreement with Suncare (Shanghai) Health Technology Co., Ltd.
Nanjing, China--(Newsfile Corp. - July 29, 2026) - Visionary Holdings Inc. (NASDAQ: GV) ("Visionary" or the "Company") today announced that its subsidiary, Nanjing Tuoyuanjian Health Technology Co., Ltd. ("GV Nanjing"), has entered into a Distribution Agreement with Suncare (Shanghai) Health Technology Co., Ltd. ("Suncare"), an AI-driven digital health and community-based senior care platform in China. Under the Distribution Agreement, GV Nanjing will supply stem cell aesthetic products
2026-07-29 9:30 AM EDT | Visionary Holdings Inc.
Sharp Therapeutics Announces Closing of Non-Brokered Private Placement
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement (the "Offering") of common shares in the capital of the Company (the "Common Shares") for aggregate gross proceeds of C$1,365,000 through the issuance of 1,500,000 Common Shares at a price of C$0.91 per Common
2026-07-29 8:45 AM EDT | Sharp Therapeutics Corp.
PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, announced today a collaboration with Craft Health Pte. Ltd. ("Craft Health") to evaluate Craft Health's CraftMake™ GMP-ready pharmaceutical 3D printing platform for PharmaTher's Personaliz3D Peptides™ partner ecosystem. The collaboration will focus on developing novel pe
Biotechnology, Pharmaceuticals
2026-07-29 8:00 AM EDT | PharmaTher Holdings Ltd.
BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the upcoming Canaccord Genuity 46th Annual Growth Conference, to be held on August 11-13, 2026, in Boston, Massachusetts. In ad
Biotechnology, Pharmaceuticals, Health
2026-07-29 8:00 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Announces Strategic Focus on Targeted M&A Expansion in Health and CPG Sectors
Vancouver, British Columbia--(Newsfile Corp. - July 29, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide a corporate update on its strategic growth initiatives as the Company actively pursues targeted merger and acquisition opportunities to further expand its presence in the health and wellness segments of the consumer packaged goods sector. Following the acquisition and successful operational rollout o
Technology, Biotechnology, Health
2026-07-29 6:00 AM EDT | Restart Life Sciences Corp.
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative medicine company is pleased to announce the VesCell™ Phase I Longevity Clinical Trial protocol has been drafted. The longevity protocol represents an important milestone in Hemostemix's strategy to expand the clinical application of VesCell™ beyond the treatment of card
Biotechnology, Pharmaceuticals, Health
2026-07-28 12:14 PM EDT | Hemostemix Inc.
BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its second quarter 2026 financial results before the market opening on Tuesday, August 11, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to discuss the r
Biotechnology, Pharmaceuticals, Health
2026-07-28 8:00 AM EDT | BioHarvest Sciences Inc.
PreveCeutical Closes Third Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated June 12, 2026, May 12, 2026 and April 22, 2026, it has closed a third tranche (the "Third Tranche") of its previously announced non-brokered private placement (the "Offering"), which Third Tranche consisted of the issuance of 8,0
Biotechnology, Pharmaceuticals, Health
2026-07-27 5:12 PM EDT | PreveCeutical Medical Inc.
PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PH
Biotechnology, Pharmaceuticals
2026-07-27 8:00 AM EDT | PharmaTher Holdings Ltd.
Optimind Pharma Announces Adoption of Semi-Annual Reporting
Toronto, Ontario--(Newsfile Corp. - July 24, 2026) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators (CSA), the pilot program under CBO 51-933 allows eligible venture issuers to voluntari
Biotechnology, Cannabis, Health, Psychedelics
2026-07-24 9:04 AM EDT | Optimind Pharma Corp.
iOrganBio Expands Scientific Advisory Board with Appointment of Lee L. Rubin, Ph.D
Morrisville, North Carolina--(Newsfile Corp. - July 23, 2026) - iOrganBio is an innovator in intelligent cell manufacturing, redefining how human cells are engineered and produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs). The company today announced the appointment of Lee L. Rubin, Ph.D., to the Company's Scientific Advisory Board. Dr. Rubin is a leading authority in stem cell biology, regenerative medicine, and tran
2026-07-23 9:14 AM EDT | iOrganBio
Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants. Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant,
Biotechnology, Pharmaceuticals, Health
2026-07-22 4:50 PM EDT | Hemostemix Inc.
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-22 12:30 PM EDT | Phio Pharmaceuticals Corp.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Canada
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - July 22, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that Vitalité Health Network has joined as the first Canadian site in its large multi-center observational data collection study to advance the development of its t
Technology, Biotechnology, Healthcare and Hospitals, Health
2026-07-22 10:00 AM EDT | Breathe BioMedical Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-22 7:00 AM EDT | Phio Pharmaceuticals Corp.
Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small molecule therapies to treat genetic diseases, is pleased to announce the voting results from its annual general meeting of shareholders held on July 21, 2026 (the "Meeting"). All nominees set forth in the Company's amended and restated management information circular
2026-07-21 5:00 PM EDT | Sharp Therapeutics Corp.
Biosenta Highlights Independent University of Calgary Research Validating Tri-Filler(TM) Antimicrobial Technology
Ontario and Calgary, Alberta--(Newsfile Corp. - July 21, 2026) - Biosenta Inc. (CSE: ZRO) ("Biosenta") today highlighted new research released by the University of Calgary demonstrating the performance of the Company's antimicrobial nanotechnology, Tri-Filler™, being developed in collaboration with researchers at the University of Calgary and the Alberta Centre for Advanced Diagnostics (ACAD). According to the University of Calgary, laboratory testing showed Tri-Fill
Biotechnology, Chemical, Household / Consumer / Cosmetics
2026-07-21 1:51 PM EDT | Biosenta Inc.
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company
Biotechnology, Healthcare and Hospitals
2026-07-21 9:17 AM EDT | Envoy Medical, Inc.